Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response

Abstract: T cells expressing CD19-targeting chimeric antigen receptors (CARs) reveal high efficacy in the treatment of B cell malignancies. Here, we report that T cell receptor fusion constructs (TRuCs) comprising an antibody-based binding domain fused to T cell receptor (TCR) subunits can effectively reprogram an intact TCR complex to recognize tumor surface antigens. Unlike CARs, TRuCs become a functional component of the TCR complex. TRuC-T cells kill tumor cells as potently as second-generation CAR-T cells, but at significant lower cytokine release and despite the absence of an extra co-stimulatory domain. TRuC-T cells demonstrate potent anti-tumor activity in both liquid and solid tumor xenograft models. In several models, TRuC-T cells are more efficacious than respective CAR-T cells. TRuC-T cells are shown to engage the signaling capacity of the entire TCR complex in an HLA-independent manner

Object Details

• Location: Deutsche Nationalbibliothek Frankfurt am Main
• Extent: Online-Ressource
• Language: Englisch
• Notes: Nature communications. - 10 (2019) , 2087, ISSN: 2041-1723

Classification and Topics

• Keyword: Krebs ; Immuntherapie ; T-Lymphozyten-Rezeptor ; Frischzellentherapie

Contributors, Places and Time

• Event: Veröffentlichung
• (where): Freiburg
• (who): Universität
• (when): 2019
• Creator: Baeuerle, Patrick Alexander ; Ding, Jian ; Patel, Ekta ; Thorausch, Niko ; Horton, Holly ; Gierut, Jessica ; Scarfo, Irene ; Choudhary, Rashmi ; Kiner, Olga ; Krishnamurthy, Janani ; Le, Bonnie ; Morath, Anna ; Baldeviano, G. Christian ; Quinn, Justin ; Tavares, Patrick ; Wei, Qi ; Weiler, Solly ; Maus, Marcela V. ; Getts, Daniel ; Schamel, Wolfgang ; Hofmeister, Robert

Further information

• DOI: 10.1038/s41467-019-10097-0
• URN: urn:nbn:de:bsz:25-freidok-1503300
• Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Last update: 15.08.2025, 7:28 AM CEST